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Natalizumab was approved for the treatment of 
active relapsing–remitting multiple sclerosis 
(RRMS) in 2006.1,2 Its main complication has been 
the risk of developing John Cunningham virus 
(JCV)-mediated3 progressive multifocal leukoen-
cephalopathy (PML), with 566 cases through June 3, 
2015.4,5 Patients are currently stratified using three 
parameters: prior immuno-suppressant use/immune 
suppression (IS), duration of natalizumab treatment, 
and presence of antibodies against the PML-inducing 
JCV.6 Unfortunately, the calculations of future PML 
incidences and, therefore, risks drawn from data 
gathered until February 2012, turned out to be under-
estimated. While Bloomgren and colleagues worked 
with an incidence of 2.13 (95% confidence interval 
1.85–2.44),6 the incidence has increased since then, 
with the most current incidence being almost twice 
as high with 3.96 (95% confidence interval 3.64–
4.30).4 This suggests that current risk stratification 
algorithms are not effective enough in preventing 
the development of new PML cases.7 This, of course, 
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Abstract
Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy 
(PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are cur-
rently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin 
(CD62L) have been proposed as additional risk stratification parameters.
Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk 
stratification.
Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV 
index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-
PML patients).
Results: CD62L values correlate with JCV serostatus, as well as JCV index values. Low CD62L in 
natalizumab-treated patients was confirmed and validated as a biomarker for PML risk with the risk factor 
“CD62L low” increasing a patient’s relative risk 55-fold (p < 0.0001). Validation efforts established 86% 
sensitivity/91% specificity for CD62L and 100% sensitivity/59% specificity for JCV index as predictors 
of PML. Using both parameters identified 1.9% of natalizumab-treated patients in the reference center as 
the risk group.
Conclusions: Both JCV index and CD62L have merit for risk stratification and share a potential bio-
logical relationship with implications for general PML etiology. A risk algorithm incorporating both 
biomarkers could strongly reduce PML incidence.
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is also due to the reluctance of patients to deal with 
their estimated PML risk, the superior efficacy of 
natalizumab,8 and the lack of alternative treatments 
in many cases.9 Recently, two new numerical param-
eters for improving individual risk stratification 
have been proposed: anti-JCV antibody titers repre-
sented as a JCV index value10 and L-selectin 
(CD62L)11,12 as a possible biomarker to indicate 
individual risk of developing PML under therapy 
with natalizumab or during human immunodefi-
ciency virus (HIV) infection.13 We integrated these 
numerical risk parameters for natalizumab-associ-
ated PML and present verification and validation 
cohorts for CD62L. Integration of JCV index and 
CD62L into risk stratification algorithms has the 
potential to significantly reduce the risk of PML dur-
ing treatment with natalizumab.
Material and methods
Patients and biomaterials
Peripheral blood mononuclear cell (PBMC) samples 
from 1410 RRMS patients and serum samples from 
1921 RRMS patients, both alongside natalizumab 
therapy, in addition to 17 patients (PBMC) and nine 
patients (serum), who later developed natalizumab-
associated PML (pre-PML), were assessed 
(Supplementary Figure 1). Furthermore, healthy 
donors’ (HD, n = 90)), systemic lupus erythematosus 
(SLE, n = 62), HIV (n = 32), lymphopenia-associ-
ated PML (n = 1), SLE-associated PML (SLE-PML; 
n = 1), HIV-associated PML (HIV-PML; n = 12), and 
acute natalizumab-associated PML (Nat-PML; n = 
19) samples were included. The study was approved 
by the local ethics committee (University of 
Muenster: Ethik-Kommission der Ärztekammer 
Westfalen-Lippe und der Medizinischen Fakultät 
der Westfälischen Wilhelms-Universität, registration 
number: 2010-245-f-S; University of Turin: Ethic 
approval number 7777 (March 25, 2013); University 
of Barcelona: ethics approval PR(AG)32/2008; 
University of Toulouse, Comite ethique du sud ouest et 
outre mer II: 2-09-02) and informed written consent 
was obtained from all participants. This study was 
performed according to the Declaration of Helsinki.
Anti-JCV antibody status and -index value
Sera samples were processed and analyzed by Unilabs 
(Copenhagen, Denmark) with the second-generation 
enzyme-linked immunosorbent assay (ELISA kit 
STRATIFY JCV™ DxSelect™14 (#EL1950, Focus 
Diagnostics, Cypress, CA, USA) according to the 
manufacturer’s instructions.10
CD62L (L-selectin) assessment
Cryopreserved PBMCs were used as biomaterials. 
Because of the retrospective assessments of the veri-
fication cohorts, standard operating procedures 
(SOPs) for cryopreservation varied. Thawing and 
staining protocols, however, were harmonized 
between centers and applied as published previously; 
the validation cohorts were cryopreserved and 
assessed strictly according to the previously pub-
lished SOPs.11 The flow cytometry gating strategy is 
shown in Figure 1. There is an inherent phenomenon 
of reduced viability/cellular integrity (CI; % of large 
CD4+ T cells within CD4+ T cells;15,16 these smaller 
lymphocytes do not express CD62L and are propid-
ium iodide (PI) positive in previously cryopreserved 
lymphocytes. Dead cells were, therefore, excluded 
from the analysis. The retrospective samples were 
analyzed in a blinded fashion. After the CD62L results 
were obtained, the patients were grouped into “con-
trol” and “pre-PML.” The CD62L results of the pro-
spective samples were reported back to physicians in 
a blinded fashion over the years. If patients later 
developed PML, these patients’ samples were then 
grouped into “pre-PML.”
Statistics
Continuous variables such as age and natalizumab 
cycles are characterized by mean and standard devia-
tion. Categorical variables, e.g. prior IS or JCV sero-
positivity are described by absolute and relative 
frequencies. Univariate correlations are estimated by 
Spearman’s correlation coefficient. Data are visual-
ized as scatterplots and supplemented by linear 
regression lines. Fisher’s exact test was used when 
calculating relative PML risks. P values are consid-
ered significant if ⩽ 0.05. No adjustment for multi-
plicity was performed. Statistical analyses were 
carried out using Prism (Version 5, GraphPad, San 
Diego, CA, USA) and SPSS (Version 22.0, IBM, 
Armonk, NY, USA).
Results
CD62L: Multicentric verification and validation
To confirm the previously published results of the dis-
covery cohort,11 CD62L values were assessed in sev-
eral patient cohorts independently (Supplementary 
Figure 1). There were two parallel approaches: 1) 
Already cryopreserved PBMC samples were assessed 
retrospectively as verification cohorts (BioNAT, 
assessed in Toulouse, France; Barcelona, assessed in 
Barcelona, Spain; Marburg, assessed in Muenster, 
Germany), and as 2) new PBMC samples were 
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Figure 1. Flow cytometry gating.
PBMC samples are gated on CD3+, then CD4+CD8–, then on large lymphocytes. Small lymphocytes are propidium iodide/PI+  
and CD62L–. CD62L+ cells are subsequently determined according to the isotype control. (a) Healthy donor sample with high CI.  
(b) Healthy donor sample with low CI. (c) Natalizumab-treated patient with low CI. PBMC: peripheral blood mononuclear cell; CI: 
cellular integrity.
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collected prospectively according to the previously 
published rigorous SOPs11 as validation cohorts 
(Turin, Italy; Mainz, Germany (both assessed locally); 
Wuerzburg and Muenster, Germany (both assessed in 
Muenster)). Of note, eight of the 17 pre-PML patients 
have been described previously.11 The retrospectively 
analyzed verification cohorts of natalizumab-treated 
MS patients (n = 497 controls + 10 pre-PML patients) 
presented with a highly significant CD62L difference 
between control patients (mean = 23.36 + –14.37) and 
patients who later developed PML (pre-PML, mean = 
5.88 + –4.34; p < 0.0001). Additionally, the samples, 
which were prospectively cryopreserved in five loca-
tions especially for cellular CD62L assessment, 
showed a mean for controls of 45.85 + –13.59 (n = 
913), which again was significantly higher than the 
values of patients who later developed PML (n = 7; 
mean = 17.11 + –13.67; p = 0.0001). A threshold for 
PML risk was calculated using the exhaustive CHi-
squared Automatic Interaction Detection (CHAID) 
algorithm with a significance level for splitting of 1%, 
resulting in a threshold of 10.42 for the retrospective 
verification cohorts, leaving 93 of 497 measured con-
trol patients (18.7%) below the threshold. In the pro-
spective validation cohorts, the threshold could be 
raised to 27.95 because of the rigorously applied SOPs 
for biomaterial shipping, processing, and measure-
ment, resulting in much higher specificity. This thresh-
old set 85 of 913 control patients (9.3%) as “CD62L 
low.” If several PBMC samples of a single patient 
were available, the lowest measured value was used 
for the cross-sectional analysis to depict the most 
accurate result of a long period of observation (up to 
five years for some patients) (Figure 2(a)). Statistical 
analysis set the relative PML risk for CD62L-low 
patients in the validation cohorts at 54.55-fold (p < 
0.0001) when compared to CD62L-normal patients. 
The sensitivity in the validation cohort was 85.7% 
(95% confidence interval 42.0–99.3) (six of seven 
patients who later developed PML were measured as 
being CD62L low) and the specificity was 90.79% 
(95% confidence interval 88.5–92.5).
Assessment of CD62L in different patient cohorts 
associated with PML risk and of the JCV index in 
a large German cohort of natalizumab-treated MS 
patients
CD62L was also assessed in several other disease 
entities with PML risk. Interestingly, occurrence of 
acute-PML also coincided with low CD62L values. 
This could be shown in SLE (one of one CD62L-low 
PML patients), HIV (11/12 CD62L-low PML 
patients), lymphopenia (one of one CD62L-low PML 
patients), and most important, natalizumab-associated 
PML (14/19 CD62L-low PML patients) in the acute 
stage of PML (Figure 3(a)). JCV index (risk threshold 
>0.9) showed a specificity of 58.77% (100%–41.23%) 
(Figure 3(b)), and JCV index was available for nine 
pre-PML patients. The threshold of 0.9 was chosen 
for maximum sensitivity, as it was shown that only 
4.4% of patients presented with values <0.9 before 
developing PML compared to 13.2% of patients pre-
senting with values <1.5.17 Five of these patients were 
non-IS and all their index values were >1.5 (Figure 
3(b)); i.e. 100% sensitivity of the JCV index in the 
five eligible JCV+ patients. However, one of these 
nine patients was JCV negative six months prior to 
PML diagnosis, leading to a sensitivity of the JCV 
serostatus in our cohort of 89%.
Correlation between the anti-JCV index value and 
CD62L expression
There was no influence of CI on the expression of 
CD62L on viable lymphocytes in healthy controls, 
SLE patients or MS patients without natalizumab 
treatment. Interestingly, there was a strong correlation 
between CI and expression of CD62L on remaining 
viable cells, especially visible in natalizumab-treated 
MS patients (Spearman rho = 0.378; p < 0.0001) 
(Figure 4(a)). The potential influence of CI on the 
JCV index value of the same blood sample was evalu-
ated in parallel. In patients treated with natalizumab, 
samples with lower JCV index showed higher CI (p = 
0.039) (Figure 4(b)). Consequently, as CI influences 
the expression of CD62L, as well as being associated 
with the risk classification of the JCV index according 
to a threshold of 0.9, natalizumab-treated patients 
with low JCV index cross-sectionally had higher 
CD62L values (n = 121; mean = 52.89) and vice versa 
(n = 122; mean = 49.43; p = 0.042) (Figure 4(c)). 
CD62L values did not differ between pre-PML 
patients and controls in freshly isolated PBMCs 
(Figure 4(d)), only in previously cryopreserved 
PMBCs. Chemically induced shedding of CD62L 
(e.g. by phorbol 12-myristate 13-acetate (PMA)) in 
fresh PBMCs did not distinguish pre-PML samples 
from controls (data not shown). Importantly, it became 
evident that the lower the CD62L value a patient had, 
the higher the probability of being JCV+ or serocon-
verting to JCV seropositivity (Figure 5(a)), leading to 
35 of 37 CD62L low patients of the Muenster cohort 
being JCV+ in their most recent serum sample. This 
also fit with the observation that CD62L and JCV 
index correlated directly (Spearman rho = −0.128; p = 
0.014) (Figure 5B). In this cross-sectional analysis of 
370 patients in the reference center, seven (1.9%) pre-
sented with both risk factors: JCV index >0.9 and 
CD62L value <27.95.
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Figure 2. CD62L: Multicentric verification and validation.
(a) CD62L values (% CD62L+ cells of live CD4+ T cells; mean: blue lines) of the retrospective verification cohorts (BioNAT, Barcelona, 
and Marburg): 497 controls: mean = 23.36 + –14.37, 10 pre-PML patients: mean = 5.88 + –4.34. Threshold: 10.42. Sensitivity: 90%, 
specificity: 81%. CD62L values of the prospective validation cohorts (Turin, Mainz, Wuerzburg, and Muenster): 913 controls: mean 
= 45.85 + –13.59, seven pre-PML patients: mean = 17.11 + –13.67. Threshold: 27.95. Sensitivity: 86%, specificity: 91%. Thresholds 
(dotted red lines) are calculated based on statistical algorithms for optimal specificity/sensitivity (exhaustive CHAID). PML: progressive 
multifocal leukoencephalopathy; CHAID: CHi-squared Automatic Interaction Detection.
(b) Given are pre-PML patient numbers, CD62L values, natalizumab infusion number at the time point of CD62L assessment, 
natalizumab infusion number at the time point of PML diagnosis, duration between the CD62L assessment and PML diagnosis, JCV 
index value, whether there was prior immune suppression, and whether this patient was published previously. Of note, a different 
sample aliquot was assessed in previously published patients.11 PML: progressive multifocal leukoencephalopathy; JCV: John 
Cunningham virus.
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Figure 3. Assessment of CD62L in different associations of PML and of JCV index in a large cohort of German patients 
treated with natalizumab.
(a) Shown are the CD62L values of the patient cohorts (% CD62L+ cells of live CD4+ T cells): HD (n = 79), SLE (n = 52), SLE-PML  
(n = 1), HIV (n = 24), HIV-PML (n = 12), lymphopenia-associated PML (n = 1; 3 time points, numbers are “months post-PML 
diagnosis”), MS patients not treated with natalizumab (MS, n = 9), MS patients treated with natalizumab and monitored in Muenster 
(Nat, n = 605), and patients suffering from acute natalizumab-associated PML (Nat-PML, n = 19). The red dotted line indicates the 
validated threshold (27.95), which sets 4% of the patients assessed in Muenster as CD62L low. The gray line is a tentatively suggested 
threshold for SLE patients at 40.6, which would set 11.5% of SLE patients as being CD62L low in their respective cohort. Statistical 
threshold determination was not possible with one SLE-PML case. PML: progressive multifocal leukoencephalopathy; HD: healthy 
donors; SLE: systemic lupus erythematosus; HIV: human immunodeficiency virus; MS: multiple sclerosis.
(b) JCV index of 1921 natalizumab-treated patients grouped according to being JCV+ (54.66%) and the index risk threshold 0.9 (41.23%), 
resulting in a specificity for the JCV index in our cohort of 58.77% (100%–41.23%). Pre-PML patients are shown in black (non-immune 
suppressed) or red (prior immune suppression). The patient, who was JCV negative before PML onset, is shown in green with a red border 
(indicating prior immune suppression). The black lines show the thresholds of 0.4 (serostatus JCV+), 0.9 (lower PML risk threshold) and 
1.5 (higher PML risk threshold). JCV: John Cunningham virus; PML: progressive multifocal leukoencephalopathy.
Multiple Sclerosis Journal 22(8)
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Discussion
The fact that current PML incidences were underesti-
mated by previous studies4,6 strengthens the need for 
efficient risk stratification parameters (especially for 
JCV+ patients), as using algorithms based on mainly 
the JCV serostatus has been only modestly successful 
in reducing the occurrence of new PML cases.7 Some 
biomarker efforts have yielded promising results in 
the recent literature.18,19 Large prospective studies 
will have to determine their usefulness, applicability, 
Figure 4. Correlation between cellular integrity (CI), JCV index and CD62L.
(a) Correlation between CI and CD62L value in the cohorts of Figure 2(b) (Nat n = 423; slope = 0.353; Spearman rho = 0.378; 
p < 0.0001). (b) CI of natalizumab-treated MS patients grouped according to JCV index value (<0.9: n = 111; and >0.9: n = 109). 
(c) CD62L value of natalizumab-treated MS patients grouped according to JCV index value (<0.9: n = 121; and >0.9: n = 122). 
(d) Shown are 105 patients (103 non-PML controls, two pre-PML patients) under long-term treatment with natalizumab. Stainings  
(as delineated in Figure 1) were performed on freshly isolated PBMCs. Samples of pre-PML patients (red) do not show reduced CD62L 
values in fresh blood. JCV: John Cunningham virus; PML: progressive multifocal leukoencephalopathy; MS: multiple sclerosis; PBMC: 
peripheral blood mononuclear cells.
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connection to other risk factors, and how they can be 
incorporated into daily clinical practice. We focused 
on the two numerical biomarkers potentially relevant 
for individual PML risk stratification during natali-
zumab therapy: JCV index and CD62L.
The different CD62L mean values of the verification 
and validation cohorts show that it is important to 
ship, process, and measure samples strictly according 
to the published SOPs11 to ensure optimal assay speci-
ficity. Within the verification and validation cohorts, 
the sensitivity of the biomarker CD62L was 90% and 
86%, respectively (nine of 10 and six of seven pre-
PML patients were CD62L low at least once). This is 
in agreement with the largest PML cohort (HIV), in 
whom CD62L showed a sensitivity of 92% during 
Figure 5. Correlation between CD62L and JCV serostatus, as well as JCV index.
(a) CD62L values of the Muenster cohort (n = 758). If patients were measured several times during the validation period, the lowest 
measured CD62L value is shown to account for the longest possible period of observation/longitudinal stability. JCV− patients are shown 
in green, JCV+ patients in red, patients who changed serostatus during the period of observation in orange, and patients with unknown 
JCV status in black. With lower CD62L values, the percentage of JCV+ patients rises steadily; 35 of 37 (95%) CD62L-low patients 
are JCV+. (b) Correlation between CD62L and JCV index in natalizumab-treated MS patients (n = 370; slope = −0.01721 ± 0.00543; 
p = 0.0017; Spearman rho = −0.128; p = 0.014). Red lines depict the thresholds for JCV index (0.9) and CD62L (27.95), and the red 
quadrant indicates the patients of this cohort set at high risk to develop PML in the future (seven of 370 = 1.9%). JCV: John Cunningham 
virus; PML: progressive multifocal leukoencephalopathy; MS: multiple sclerosis.
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acute PML. Importantly, these results were achieved 
using random assessment intervals and with a mean 
duration of 19.3 months between the last CD62L 
assessment and PML diagnosis and should, therefore, 
be higher with regular (e.g. bi-yearly) monitoring. 
Based on the validation cohorts, a proposed risk strat-
ification algorithm would set a small group of MS 
patients at high risk (CD62L low combined with 
being JCV+ and a) either IS or b) JCV index >0.9) 
(Figure 6). CD62L specificity can be >91% with opti-
mal SOPs (e.g. in the Muenster reference center, 96% 
of control patients stay above the CD62L threshold 
over time and only 1.9% of patients present with both 
risk factors). While retrospective cohorts are mainly 
important for reproduction purposes, showing that the 
assay works per se, standardized prospective cohorts 
can be used for threshold discussions and daily clini-
cal practice.
Analogous to the JCV index, one single CD62L 
threshold of 27.95 will not be ideal for every cohort, 
but also not for every circumstance, as risk stratifica-
tion is multiparametric and individual. While statis-
tics and distributions set this threshold for optimal 
sensitivity and specificity during validation, it might 
be that a patient with other treatment options might 
decide that, personally, a CD62L value above that 
threshold is unacceptable, whereas a patient with lim-
ited therapeutic alternatives might want to stay on 
treatment even with a lower value.
Low CD62L values seem to be associated with PML 
in all constellations we looked at (natalizumab, rituxi-
mab, efalizumab,11 HIV,13 SLE and lymphopenia), 
leading us to conclude that the biomarker might be 
generally applicable for PML risk assessment and 
suggesting a common PML etiology in all of these 
instances: In total, 46 of 54 patients (85%) from all 
PML associations and stages presented with the risk 
factor CD62L low.
In this study, we were able to demonstrate that known 
PML risk parameters such as natalizumab treatment 
duration, JCV index, and CD62L value are related in 
various ways. This suggests that these risk factors are 
indicators for a “status” of the immune system, which 
would make a patient vulnerable specifically to the 
development of PML. This connection is also strongly 
supported by the correlation between JCV index and 
CD62L value in the same blood sample, leading to the 
finding that 96% of patients who presented with even 
one CD62L-low PBMC sample, were JCV+ in their 
most recent serum sample. As a further confirmation, 
it was recently shown that in addition to the cellular 
Figure 6. Suggested PML risk stratification algorithm.
Suggested risk stratification algorithm integrating JCV index and L-selectin. This suggested algorithm shows how to incorporate 
JCV index value and L-selectin into clinical practice. Statistically, adherence to this scheme should avoid most future PML cases by 
considering a change in treatment in a few patients. In short, natalizumab-treated patients should be tested for JCV serology and CD62L. 
JCV+ CD62L-low patients should consider treatment alternatives, unless they are not immune suppressed and their JCV index is <0.9.
PML: progressive multifocal leukoencephalopathy; JCV: John Cunningham virus; RRMS: relapsing–remitting multiple sclerosis.
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form, soluble CD62L also correlates with JCV index 
in natalizumab-treated MS patients.20
In a similar line of thought it makes sense that in the 
first 17 months of treatment, when the PML incidence 
is much lower, none of 69 patients was set as CD62L 
low. As previous hypotheses concerning JCV titers 
suggested that higher titers are the result of a higher 
replication rate of the virus,21–23 it is conceivable that a 
higher replication rate is due to the fact that the less-
viable immune cells of this patient are less capable of 
suppressing viral activity. Consistent with the fact that 
samples with low CI show less CD62L after thawing, 
which is a stressful event for the cells, both numerical 
risk parameters (high JCV index and low CD62L) 
might potentially be the downstream result of a dys-
functional immune status, albeit assessing different 
parts of the immune system: humoral and cellular. 
Remarkably, changes in CI related to CD62L loss on 
live cells were especially strong in natalizumab-treated 
patients. Reduced CI leads to lower CD62L levels and 
higher JCV index values, both associated with 
enhanced PML risk. The CD62L value should, there-
fore, really be regarded as a very specific immune cell 
stress indicator due to the freezing/thawing procedure. 
This point of view is supported by the fact that in fresh 
blood stainings, the CD62L value of pre-PML patients 
is not reduced.
CD62L is for several reasons not useful for diagnosing 
acute PML: First and foremost, the procedure includ-
ing cryopreservation and waiting periods takes roughly 
three weeks to perform with rigorous SOPs, rendering 
any result useless for immediate treatment decisions. 
Secondly, the sensitivity of the assay in acute PML 
patients is currently only 74% (14/19 acute PML 
patients were measured as CD62L low), possibly due 
to the different nature of the PML associations natali-
zumab versus HIV, which causes 91.7% of patients to 
stay CD62L low during acute PML. However, the 
results from the cohort of patients suffering from acute 
natalizumab-associated PML strongly support the 
validity of CD62L as a risk biomarker for PML and 
also support the chosen thresholds. Of note, one of the 
acute-PML cases was tested as JCV seronegative six 
months prior to PML diagnosis, but presented with a 
low CD62L value at diagnosis.
Recently, the manufacturer of natalizumab (Biogen) 
investigated CD62L as a potential PML risk biomarker24 
and could show that eight out of nine pre-PML patients 
presented with at least one low CD62L value. The ninth 
pre-PML patient presented as CD62L low only during 
acute PML. Because of the retrospective nature of this 
specific study, the mean of control patients and the lon-
gitudinal stability of CD62L were reduced, similar to 
what we observed in our retrospective cohorts. This 
strongly reduced the specificity of the marker. However, 
our data clearly show that prospective assessment and 
rigorous adherence to SOPs for clinical diagnostics 
solve this problem. The group of Professor Bertolotto 
(Turin) successfully reproduced the results of the initial 
study independently by following SOPs and suggests 
that CD62L might be a valid biomarker for PML risk 
during natalizumab treatment.25
Both numerical biomarkers of PML risk prediction 
have strengths and weaknesses. The JCV index is 
determined from serum, which is easy to ship. The 
index’s overall sensitivity is difficult to judge, as a) 
it does not work for IS patients, who make up a large 
proportion of PML patients and, therefore, the eligi-
ble cohort is reduced and b) there are at least four 
JCV patients (who, therefore, had an index value of 
<0.4) who developed PML,4 but these patients are 
not discussed in the index publication, because the 
paper describes only JCV+ (pre-PML) patients. One 
of these JCV-seronegative patients is shown in this 
publication. Based on the currently available data, 
the sensitivity of the JCV index in anti-JCV anti-
body-positive patients without prior immunosup-
pressant use is, therefore, 96% (65/68), based on the 
0.9 index cutoff.10,17,26 If the JCV-seronegative PML 
cases are included, the combined sensitivity of the 
JCV serology will be lower than that. Additionally, 
its specificity of detecting patients at risk is low at 
58.77%. CD62L, on the other hand, is a parameter 
measured in PBMCs isolated from ethylenediamine-
tetraacetic acid (EDTA) blood with all its inherent 
challenges of shipment and storage, but its current 
sensitivity of 86%–88% and specificity of 91%–96% 
can be considered very high and it works in patients 
with prior IS. Moreover, for CD62L, being a dynamic 
biomarker, we emphasize that patients with one nor-
mal value are not free of risk, as they could have 
been CD62L low earlier. However, close monitoring 
from the start of therapy on can mitigate this prob-
lem and the marker should, therefore, be regarded as 
a qualitative risk factor, similar to IS: A patient 
tested as CD62L low even once has a statistically 
validated 55-fold higher risk of later developing 
PML. As there are few situations conceivable that 
might in singular cases lead to false-positive results 
(e.g. heart attack,24 immediate pre-treatment with 
fingolimod (data not shown), or acute urosepsis27), 
physicians should try to assess their patients during 
periods with low interference by concomitant treat-
ments or afflictions.
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The next step for the implementation of the biomarker 
could be the setup of standardized and validated labo-
ratories in each country where natalizumab is being 
prescribed, to allow for a manageable and easy assess-
ment of CD62L in daily clinical practice. This, how-
ever, is beyond the scope of an academic center and 
should be pursued by the pharmaceutical industry.
Ultimately, natalizumab is still one of the most effica-
cious treatments available today, and risk stratifica-
tion during treatment with natalizumab is about 
individual risk perception and tolerance. The system-
atic inclusion of both JCV index and CD62L could 
reduce the risk and occurrence of PML up to 10-fold 
if applied rigorously during risk stratification.
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